We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Tiziana Life Sciences plc (TLSA) NPV

Sell:$0.67 Buy:$0.71 Change: $0.026 (4.06%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Sell:$0.67
Buy:$0.71
Change: $0.026 (4.06%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Sell:$0.67
Buy:$0.71
Change: $0.026 (4.06%)
Market closed |  Prices as at close on 19 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.

Contact details

Address:
3Rd Floor, 11-12 St. James's Square
LONDON
SW1Y 4LB
United Kingdom
Telephone:
+44 (20) 74952379
Website:
https://www.tizianalifesciences.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TLSA
ISIN:
BMG889121031
Market cap:
$52.47 million
Shares in issue:
102.27 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Bermuda
Currency:
US dollar
Indices:
n/a

Key personnel

  • Gabriele Cerrone
    Executive Chairman of the Board
  • Kunwar Shailubhai
    Chief Executive Officer, Chief Scientific Officer, Executive Director
  • Keeren Shah
    Finance Director
  • Jules Jacob
    Senior Director, CMC and Non - Clinical Development
  • William Clementi
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.